The FDA’s Center for Devices and Radiological Health issued a discussion paper on generative AI-enabled medical devices that seeks stakeholder input on risk assessment, premarket evaluation, and postmarket monitoring without proposing policy changes. The paper identifies potential risks including hallucinations, performance degradation, and limited model transparency while emphasizing least-burdensome principles for timely patient access. All reported details originate from a single primary source with right-leaning bias.